Invention Grant
- Patent Title: Substituted inhibitors of menin-MLL and methods of use
-
Application No.: US16647855Application Date: 2018-09-19
-
Publication No.: US11649251B2Publication Date: 2023-05-16
- Inventor: Tao Wu , Liansheng Li , Pingda Ren
- Applicant: Kura Oncology, Inc.
- Applicant Address: US CA San Diego
- Assignee: KURA ONCOLOGY, INC.
- Current Assignee: KURA ONCOLOGY, INC.
- Current Assignee Address: US CA San Diego
- Agency: Wilson Sonsini Goodrich & Rosati
- International Application: PCT/US2018/051666 2018.09.19
- International Announcement: WO2019/060365A 2019.03.28
- Date entered country: 2020-03-16
- Main IPC: C07D495/04
- IPC: C07D495/04 ; A61K31/519 ; C07D519/00 ; A61P35/00 ; C07D471/10 ; C07D487/04 ; C07D487/10 ; A61K9/00
Abstract:
The present disclosure provides methods of inhibiting the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The methods are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin. Compositions for use in these methods are also provided.
Public/Granted literature
- US20200216471A1 SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHODS OF USE Public/Granted day:2020-07-09
Information query
